Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration

Andrea CALCAGNO; C Pinnetti; A De Nicolò; E Scarvaglieri; M Gisslen; M Tempestilli; D'Avolio Antonio; V Fedele; G Di Perri; A Antinori; S Bonora

doi:10.1111/bcp.13552

Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration

Andrea CALCAGNO
, C Pinnetti
, A De Nicolò
, E Scarvaglieri
, M Gisslen
, M Tempestilli
, D'Avolio Antonio
, V Fedele
, G Di Perri
, A Antinori
, S Bonora

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Abacavir is a widely used nucleotide reverse transcriptase inhibitor whose cerebrospinal fluid (CSF) exposure has been previously assessed in twice-daily recipients. We studied abacavir CSF concentrations in 61 and 9 HIV-positive once-daily and twice-daily abacavir intakers. Patients on once-daily abacavir had higher plasma and CSF concentrations (96 vs. 22 ng/mL, p=0.038 and 123 vs. 49 ng/mL, p=0.038) but similar CSF-to-plasma ratios (0.8 vs. 0.5, p=0.500). CSF abacavir concentrations were adequate in once-daily receiving patients.

Lingua originale	Inglese
pagine (da-a)	1-4
Numero di pagine	4
Rivista	British Journal of Clinical Pharmacology
Volume	1
Numero di pubblicazione	1
DOI	https://doi.org/10.1111/bcp.13552
Stato di pubblicazione	Pubblicato - 2018

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

abacavir
age
central nervous system
cerebrospinal fluid
pharmacokinetics
protease inhibitors

Accesso al documento

10.1111/bcp.13552

https://hdl.handle.net/11579/216885

Altri file e collegamenti

handle

Cita questo

@article{1145539a8dbe4d488d9f37e5d72f9bb7,

title = "Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration",

abstract = "Abacavir is a widely used nucleotide reverse transcriptase inhibitor whose cerebrospinal fluid (CSF) exposure has been previously assessed in twice-daily recipients. We studied abacavir CSF concentrations in 61 and 9 HIV-positive once-daily and twice-daily abacavir intakers. Patients on once-daily abacavir had higher plasma and CSF concentrations (96 vs. 22 ng/mL, p=0.038 and 123 vs. 49 ng/mL, p=0.038) but similar CSF-to-plasma ratios (0.8 vs. 0.5, p=0.500). CSF abacavir concentrations were adequate in once-daily receiving patients.",

keywords = "abacavir, age, central nervous system, cerebrospinal fluid, pharmacokinetics, protease inhibitors, abacavir, age, central nervous system, cerebrospinal fluid, pharmacokinetics, protease inhibitors",

author = "Andrea CALCAGNO and C Pinnetti and \{De Nicol{\`o}\}, A and E Scarvaglieri and M Gisslen and M Tempestilli and D'Avolio Antonio and V Fedele and \{Di Perri\}, G and A Antinori and S Bonora",

year = "2018",

doi = "10.1111/bcp.13552",

language = "English",

volume = "1",

pages = "1--4",

journal = "British Journal of Clinical Pharmacology",

issn = "0306-5251",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

TY - JOUR

T1 - Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration

AU - CALCAGNO, Andrea

AU - Pinnetti, C

AU - De Nicolò, A

AU - Scarvaglieri, E

AU - Gisslen, M

AU - Tempestilli, M

AU - Antonio, D'Avolio

AU - Fedele, V

AU - Di Perri, G

AU - Antinori, A

AU - Bonora, S

PY - 2018

Y1 - 2018

N2 - Abacavir is a widely used nucleotide reverse transcriptase inhibitor whose cerebrospinal fluid (CSF) exposure has been previously assessed in twice-daily recipients. We studied abacavir CSF concentrations in 61 and 9 HIV-positive once-daily and twice-daily abacavir intakers. Patients on once-daily abacavir had higher plasma and CSF concentrations (96 vs. 22 ng/mL, p=0.038 and 123 vs. 49 ng/mL, p=0.038) but similar CSF-to-plasma ratios (0.8 vs. 0.5, p=0.500). CSF abacavir concentrations were adequate in once-daily receiving patients.

AB - Abacavir is a widely used nucleotide reverse transcriptase inhibitor whose cerebrospinal fluid (CSF) exposure has been previously assessed in twice-daily recipients. We studied abacavir CSF concentrations in 61 and 9 HIV-positive once-daily and twice-daily abacavir intakers. Patients on once-daily abacavir had higher plasma and CSF concentrations (96 vs. 22 ng/mL, p=0.038 and 123 vs. 49 ng/mL, p=0.038) but similar CSF-to-plasma ratios (0.8 vs. 0.5, p=0.500). CSF abacavir concentrations were adequate in once-daily receiving patients.

KW - abacavir

KW - age

KW - central nervous system

KW - cerebrospinal fluid

KW - pharmacokinetics

KW - protease inhibitors

KW - abacavir

KW - age

KW - central nervous system

KW - cerebrospinal fluid

KW - pharmacokinetics

KW - protease inhibitors

UR - https://iris.uniupo.it/handle/11579/216885

U2 - 10.1111/bcp.13552

DO - 10.1111/bcp.13552

M3 - Article

SN - 0306-5251

VL - 1

SP - 1

EP - 4

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

IS - 1

ER -

Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration

Abstract

OSS delle Nazioni Unite

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo